Antigen | Reactivity | Application | Clone | InVivoMab Catalog |
InVivoPlus Catalog |
B220 | mouse | in vivo B cell depletion, in vitro B cell negative selection | RA3.3A1/6.1 | BE0067 | |
B7-1 (CD80) | mouse | in vivo B7-1 blockade, Affinity chromatography | 1G10 | BE0134 | |
BTLA (CD272) | mouse | in vivo BTLA+ B cell and CD4 T cell depletion, FC | 6F7 | BE0304 | |
c-Kit (CD117) | mouse | FC, IF, IHC | 2B8 | BE0280 | |
CCR3 (CD193) | mouse | in vivo eosinophil depletion | 6S2-19-4 | BE0316 | |
CD1a | human | in vivo CD1a blockade, FC | OKT-6 | BE0211 | |
CD1d (CD1.1) | mouse | in vivo CD1d blockade, iNKT cell neutralization, FC | 20H2 (HB323) | BE0179 | |
CD3 | mouse | in vivo T cell stimulation/activation | 17A2 | BE0002 | |
CD3ɛ | mouse | in vivo T cell depletion, in vitro T cell stimulation/activation, IF, FC | 145-2C11 | BE0001-1 | BP0001-1 |
CD4 | human | in vivo CD4 blockade, in vitro blocking of CD4+ T cell activation, IF, IHC-F, FC | RPA-T4 | BE0288 | |
CD8α | human | in vivo CD8+ T cell depletion in humanized mice | OKT-8 | BE0004-2 | |
CD8β (Lyt 3.2) | mouse | in vivo CD8+ T cell depletion, in vivo CD8 blockade, IF | 53-5.8 | BE0223 | |
CD11b | mouse/human | in vivo CD11b neutralization, ILC2 cell purification, FC | M1/70 | BE0007 | |
CD19 | human | Functional assays, Chimeric antigen receptor construction, FC, IF | 4G7 | BE0281 | |
CD22 | mouse | in vivo B cell depletion in combination with anti-CD19 (clone 1D3) and anti-rat κ Light Chain (clone MAR 18.5), FC, IP | Cy34.1 | BE0011 | |
CD28 | mouse | in vivo T cell stimulation/activation, in vivo CD28 blockade | 37.51 | BE0015-1 | |
CD40L (CD154) | human/monkey | in vivo and in vitro blocking of CD40/CD40L signaling, IP, FC | 5C8 | BE0292 | |
IFNγRα (CD119) | mouse | WB, IP, FC | 2E2 | BE0287 | |
IL-10 | mouse | in vivo IL-10 neutralization, in vitro IL-10 neutralization | JES5-2A5 | BE0049 | |
IL-12 | mouse | in vivo IL-12 neutralization | R1-5D9 | BE0052 | |
IL-12 p70 | human | Functional assays, ELISA, FC | 20C2 | BE0234 | |
IL-15 | mouse | in vivo and in vitro IL-15 neutralization | AIO.3 | BE0315 | |
IL-1β | mouse/rat | in vivo and in vitro IL-1β neutralization, ELISA | B122 | BE0246 | |
IL-2 | mouse | in vivo and in vitro IL-2 neutralization, in vivo IL-2 receptor stimulation (as a complex with IL-2), ELISPOT, FC | JES6-5H4 | BE0042 | |
IL-3 | mouse | in vivo and in vitro IL-3 neutralization, in vivo IL-3 receptor stimulation (as a complex with IL-3), ELISA, FC | MP2-8F8 | BE0282 | |
IL-6 | mouse | in vivo IL-6 neutralization, in vitro IL-6 neutralization | MP5-20F3 | BE0046 | |
IL-7 | mouse/human | in vivo IL-7 neutralization, in vivo IL-7 receptor stimulation (as a complex with IL-7) | M25 | BE0048 | |
IL-9 | human | FC, ELISA | MH9A4 | BE0327 | |
Ly6G/Ly6C (Gr-1) | mouse | in vivo depletion of Gr-1+ myeloid cells, FC, IHC-P, IHC-F | RB6-8C5 | BE0075 | BP0075 |
PD-1 (CD279) | mouse | in vivo blocking of PD-1/PD-L signaling, in vitro PD-1 neutralization, IHC-F, FC, WB | 29F.1A12 | BE0273 | BP0273 |
PD-L1 (B7-H1) | human | in vitro PD-L1 blockade, Functional assays, IHC-F, FC | 29E.2A3 | BE0285 | |
PD-L2 (B7-DC) | mouse | in vivo PD-L2 blockade, in vitro PD-L2 blockade, IHC-F, FC | TY25 | BE0112 | |
Siglec-H | mouse | in vivo administration, FC | 440c | BE0202 | |
TCR Vγ1.1/Cr4 | mouse | FC | 2.11 | BE0257 | |
TCR γ/δ | mouse | in vivo TCR γ/δ neutralization, in vitro γ/δ T cell stimulation, in vitro γ/δ T cell purification, Functional assays, IP, FC | UC7-13D5 | BE0070 | |
TCRβ | mouse | in vivo T cell depletion | H57-597 (HB218) | BE0102 | |
Ter-119 | mouse | in vivo administration, Functional assays, FC | TER-119 | BE0183 | |
Thy1 (CD90) | mouse | in vitro T cell depletion | M5/49.4.1 | BE0076 | |
Thy1.2 (CD90.2) | mouse | in vivo ILC depletion, in vivo T cell depletion | 30H12 | BE0066 | BP0066 |
TIGIT | mouse | in vivo TIGIT stimulation, FC | 1G9 | BE0274 | |
TIM-1 (CD365) | mouse | in vivo TIM-1 activation, in vitro T cell stimulation/activation, Functional assays, ELISA, FC | 3B3 |